Latest News

A review of 12 studies showed that maternal migraine was linked to a higher likelihood of infant colic, and that infant colic was in turn linked to a higher risk of migraine later in childhood.

Here's some of what is coming soon to NeurologyLive® this week.

Emerging therapies for muscular dystrophy are targeting a range of disease mechanisms, from RNA-based approaches and muscle-directed delivery to cell therapy and DUX4 suppression.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is emerging muscular dystrophy agents!

The AHA and ASA have replaced their 2016 stroke rehabilitation guideline with expanded, evidence-graded recommendations helping clinicians decide on care settings, comorbidity management, and long-term recovery support.

A new case report underscored the need to consider CNS lymphoproliferative disease when patients on chronic immunosuppression for neuromyelitis optica spectrum disorder develop unexplained neurologic decline.

FDA approval of apitegromab introduces a muscle-targeting approach to SMA treatment, with phase 3 data demonstrating motor-function benefit when added to existing SMN2-directed therapies.

Rory Siegel, DO, discusses the emerging evidence linking football participation with ALS, the potential role of repetitive head impacts, and key questions that remain about long-term neurological risk.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 11, 2026.

The phase 3 LUNA study showed that atogepant, an oral calcitonin gene-related peptide receptor antagonist, significantly reduced perimenstrual migraine days among patients with menstrual migraine compared with placebo.

The AAN and AHS have replaced their 2012 migraine prevention guideline with new, evidence-graded recommendations, giving neurologists clearer direction on when to start preventive therapy, how to choose among older and newer options, and how to adjust treatment for specific patients.

The FDA granted priority review to satralizumab for MOGAD, positioning it to become the first approved treatment for the rare autoimmune disease.

A newly launched global phase 3 trial will compare once-daily trientine to D-penicillamine as a first-line treatment for patients with Wilson disease, a rare genetic disorder.